Contribution of PET/CT to prediction of outcome in children and young adults with rhabdomyosarcoma

Journal of Nuclear Medicine

Volumn 52, Issue 10, 2011, Pages 1535-1540

  Baum, Sven H ^a   Frühwald, Michael ^a   Rahbar, Kambiz ^a   Wessling, Johannes ^a   Schober, Otmar ^a   Weckesser, Matthias ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

18F FDG PET CT; Prognosis; Rhabdomyosarcoma; Risk stratification

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RADIOACTIVITY; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; SCHOOL CHILD; SURVIVAL RATE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 80053529533     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.082511     Document Type: Article

References (23)

1. Dagher R, Helman L. Rhabdomyosarcoma: an overview. Oncologist. 1999;4: 34-44. (Pubitemid 29102453)
2. Qualman SJ, Coffin CM, Newton WA, et al. Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr Dev Pathol. 1998;1:550-561. (Pubitemid 128542175)
3. Parham DM. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod Pathol. 2001;14:506-514. (Pubitemid 32448750)
4. Pappo AS, Anderson JR, Crist WM, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol. 1999;17:3487-3493. (Pubitemid 29517919)
5. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study- IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001;19:3091-3102. (Pubitemid 32567502)
6. Raney RB, Maurer HM, Anderson JR, et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma. 2001;5: 9-15. (Pubitemid 32319864)
7. Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol. 2001;23:215-220. (Pubitemid 32524925)
8. Dantonello TM, Int-Veen C, Harms D, et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol. 2009;27:1446-1455.
9. Brecht IB, Treuner J. Soft tissue sarcoma in children and adolescents: experiences of the cooperative Soft Tissue Sarcoma Group Studies (CWS-81 - 96). Handchir Mikrochir Plast Chir. 2004;36:275-281. (Pubitemid 39452527)
10. Van Rijn RR, Wilde JC, Bras J, Oldenburger F, McHugh KM, Merks JH. Imaging findings in noncraniofacial childhood rhabdomyosarcoma. Pediatr Radiol. 2008;38:617-634.
11. Klem ML, Grewal RK, Wexler LH, Schoder H, Meyers PA, Wolden SL. PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools. J Pediatr Hematol Oncol. 2007;29:9-14. (Pubitemid 46143019)
12. Lucas JD, O'Doherty MJ, Cronin BF, et al. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg. 1999;86:550-556. (Pubitemid 29195057)
13. Folpe AL, Lyles RH, Sprouse JT, Conrad EU III, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000;6:1279-1287. (Pubitemid 30226209)
14. 99mTc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med. 2002;43:1012-1017.
15. Brenner W, Conrad EU, Eary JF. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur J Nucl Med Mol Imaging. 2004;31: 189-195. (Pubitemid 38173693)
16. Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 2005;103:339-348. (Pubitemid 40129294)
17. Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging. 2002;29:1149-1154. (Pubitemid 34985359)
18. Ben Arush MW, Bar Shalom R, Postovsky S, et al. Assessing the use of FDGPET in the detection of regional and metastatic nodes in alveolar rhabdomyosarcoma of extremities. J Pediatr Hematol Oncol. 2006;28:440-445. (Pubitemid 44114552)
19. McCarville MB, Christie R, Daw NC, Spunt SL, Kaste SC. PET/CT in the evaluation of childhood sarcomas. AJR. 2005;184:1293-1304. (Pubitemid 43821916)
20. Tateishi U, Hosono A, Makimoto A, et al. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med. 2009;23:155-161.
21. Gerth HU, Juergens KU, Dirksen U, Gerss J, Schober O, Franzius C. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. J Nucl Med. 2007;48:1932-1939. (Pubitemid 350237602)
22. Dantonello TM, Int-Veen C, Winkler P, et al. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. J Clin Oncol. 2008;26:406-413. (Pubitemid 351171692)
23. Völker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol. 2007;25:5435-5441. (Pubitemid 350232220)